Alunbrig

Takeda launches value-based pricing program for lung cancer med Alunbrig, promises more deals to come
Fierce Pharma
Mon, 11/8/21 - 10:54 am
Takeda
Alunbrig
value-based pricing
drug pricing
lung cancer
Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC
Pharmaceutical Business Review
Tue, 02/25/20 - 10:19 am
Takeda
Alunbrig
brigatinib
FDA
priority review
non-small cell lung cancer
Takeda sets sights on first-line lung cancer market with new Alunbrig data
Pharmaforum
Mon, 11/25/19 - 09:49 am
Takeda
Alunbrig
clinical trials
Pfizer
Xalkori
ALK-positive non-small cell lung cancer
Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori
Fierce Pharma
Sat, 11/23/19 - 04:12 pm
Pfizer
Xalkori
ALK-positive non-small cell lung cancer
Takeda
Alunbrig
NICE backs Takeda’s Alunbrig in second-line lung cancer
Pharmaforum
Sat, 02/16/19 - 12:02 am
NICE
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
CP Wire
Fri, 10/19/18 - 09:19 am
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
Fri, 10/19/18 - 09:05 am
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
CP Wire
Tue, 09/25/18 - 09:42 am
Takeda
Alunbrig
non-small cell lung cancer
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
Tue, 09/25/18 - 09:33 am
Takeda
Alunbrig
non-small cell lung cancer
More Positive Results For Takeda's Alunbrig Acquisition
CP Wire
Wed, 07/25/18 - 09:34 am
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
More Positive Results For Takeda's Alunbrig Acquisition
Wed, 07/25/18 - 08:49 am
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
Takeda's Ariad deal pays off with blockbuster green light for Alunbrig
Fierce Pharma
Sat, 04/29/17 - 10:04 am
Takeda
Ariad Pharmaceuticals
Alunbrig
ALK-positive non-small cell lung cancer